VENTURE CAPITAL POST

GSK said that it was reorganizing its cooperation with CureVac, including gaining control over various vaccines they were producing together, including COVID-19 and influenza vaccines.

The Food and Drug Administration approved Merck’s new vaccine, Capvaxive, which was designed to protect adults from a bacteria known as pneumococcus that could cause serious illnesses like pneumonia, but is yet to face the CDC’s scrutiny.

GSK has announced that the FDA has expanded the approval of its respiratory syncytial virus (RSV) vaccine, Arexvy, to those aged 50 to 59.

The US and Europe are considering acquiring or producing H5N1 bird flu vaccines to protect poultry and dairy workers.

Moderna expands its vaccine portfolio with three new candidates targeting norovirus, Epstein-Barr virus, and shingles amid demand for Covid-19 vaccines worldwide.

Self.made billionaire Sean Parker continues his vision on advancing medical researches. His Parker Institute for Cancer Immunotherapy collaborated with the Cancer Research Institute in an effort to use algorith in uncovering neoantigens.

The president of Russia, Vladimir Putin, announced that his country had found two vaccines to cure Ebola. However, the announcement has drawn some skepticism among experts who have previously developed other vaccines for Ebola.

Two tiny companies are preparing to challenge some of the world's largest drug makers in the battle for dominance in the $3 billion global market for influenza vaccines, armed with little more than tiny tobacco plants.

Hookipa Biotech AG, whose Vaxwave Technology, would help in the furtherance of infectious disease control and cancer management.

immatics raises EUR34 million in its latest Series D round financing.